In congruence with this notion, numerous preclinical models have shown that administering anti-TIGIT antibodies alongside anti-PD-1 or PD-L1 inhibitors results in nearly complete tumor remission, whereas treatment with anti-TIGIT antibodies alone elicits limited efficacy [19]. Here, CD274 is linked to neoplasm.